{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:11:06Z","timestamp":1793383866996,"version":"4.5.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1136\/ard.2010.134684","type":"journal-article","created":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T06:28:18Z","timestamp":1287469698000},"page":"1898-1906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":256,"title":["State-of-the-art: rheumatoid arthritis"],"prefix":"10.1016","volume":"69","author":[{"given":"Iain B","family":"McInnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R","family":"O'Dell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2010.134684_bib1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1136\/ard.2007.076679","article-title":"Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis","volume":"67","author":"Majka","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.134684_bib2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.bor.0000158150.57154.f9","article-title":"Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions","volume":"17","author":"Sattar","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.2010.134684_bib3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1146\/annurev.immunol.26.021607.090244","article-title":"Immunity to citrullinated proteins in rheumatoid arthritis","volume":"26","author":"Klareskog","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1136\/ard.2010.134684_bib4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(09)60008-8","article-title":"Rheumatoid arthritis","volume":"373","author":"Klareskog","year":"2009","journal-title":"Lancet"},{"key":"10.1136\/ard.2010.134684_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/01.bor.0000155361.83990.5b","article-title":"Hypoxia and angiogenesis in rheumatoid arthritis","volume":"17","author":"Taylor","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.2010.134684_bib6","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1126\/science.1137306","article-title":"Cadherin-11 in synovial lining formation and pathology in arthritis","volume":"315","author":"Lee","year":"2007","journal-title":"Science"},{"key":"10.1136\/ard.2010.134684_bib7","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/ard.2007.078014","article-title":"Inflammasomes and rheumatic diseases: evolving concepts","volume":"67","author":"Sidiropoulos","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.134684_bib8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11926-009-0051-z","article-title":"The role of toll-like receptors in rheumatoid arthritis","volume":"11","author":"Huang","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"10.1136\/ard.2010.134684_bib9","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1002\/art.24140","article-title":"Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis","volume":"58","author":"Ospelt","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib10","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2353\/ajpath.2007.060657","article-title":"The Toll-like receptor adaptor proteins MyD88 and Mal\/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis","volume":"170","author":"Sacre","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1136\/ard.2010.134684_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1172\/JCI32639","article-title":"Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis","volume":"118","author":"Abdollahi-Roodsaz","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1136\/ard.2010.134684_bib12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1371\/journal.pmed.0060001","article-title":"Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium","volume":"6","author":"Humby","year":"2009","journal-title":"PLoS Med"},{"key":"10.1136\/ard.2010.134684_bib13","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1002\/art.24913","article-title":"The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study","volume":"60","author":"Klaasen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib14","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2353\/ajpath.2008.070703","article-title":"Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP- dendritic cells with distinct cytokine profiles","volume":"172","author":"Lebre","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1136\/ard.2010.134684_bib15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4049\/jimmunol.182.2.963","article-title":"Plasmacytoid dendritic cells regulate breach of self-tolerance in autoimmune arthritis","volume":"182","author":"Jongbloed","year":"2009","journal-title":"J Immunol"},{"key":"10.1136\/ard.2010.134684_bib16","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1186\/ar1864","article-title":"Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis","volume":"8","author":"Jongbloed","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard.2010.134684_bib17","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/ard.2009.110502","article-title":"Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis","volume":"69","author":"Baldwin","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.134684_bib18","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1172\/JCI36389","article-title":"Evidence that cytokines play a role in rheumatoid arthritis","volume":"118","author":"Brennan","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1136\/ard.2010.134684_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/ar2680","article-title":"The biological and clinical importance of the \u2018new generation\u2019 cytokines in rheumatic diseases","volume":"11","author":"Gabay","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard.2010.134684_bib20","doi-asserted-by":"crossref","first-page":"R784","DOI":"10.1186\/ar1733","article-title":"Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin","volume":"7","author":"Raza","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard.2010.134684_bib21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrrheum.2009.179","article-title":"IL-17 as a future therapeutic target for rheumatoid arthritis","volume":"5","author":"van den Berg","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard.2010.134684_bib22","doi-asserted-by":"crossref","first-page":"10913","DOI":"10.1073\/pnas.0801898105","article-title":"IL-33 exacerbates antigen-induced arthritis by activating mast cells","volume":"105","author":"Xu","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1136\/ard.2010.134684_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/BOR.0b013e32832a0760","article-title":"Anticytokine therapy impacting on B cells in autoimmune diseases","volume":"21","author":"Daridon","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.2010.134684_bib24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2174\/092986707780362826","article-title":"The contribution of adipose tissue and adipokines to inflammation in joint diseases","volume":"14","author":"Toussirot","year":"2007","journal-title":"Curr Med Chem"},{"key":"10.1136\/ard.2010.134684_bib25","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/art.23386","article-title":"Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis","volume":"58","author":"Stanczyk","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib26","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/art.24717","article-title":"Liver X receptor agonism promotes articular inflammation in murine collagen-induced arthritis","volume":"60","author":"Asquith","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib27","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1124\/jpet.105.093807","article-title":"Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation","volume":"316","author":"Kelso","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1136\/ard.2010.134684_bib28","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1002\/art.23992","article-title":"Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial","volume":"58","author":"Weinblatt","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib29","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.autrev.2007.11.019","article-title":"Circadian rhythms in arthritis: hormonal effects on the immune\/inflammatory reaction","volume":"7","author":"Cutolo","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard.2010.134684_bib31","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/ncprheum0601","article-title":"Neuroendocrine-immune interactions in synovitis","volume":"3","author":"Cutolo","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1136\/ard.2010.134684_bib32","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/art.23869","article-title":"Disrupted brain-immune system-joint communication during experimental arthritis","volume":"58","author":"del Rey","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib33","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.24470","article-title":"The alpha7 nicotinic acetylcholine receptor on fibroblast-like synoviocytes and in synovial tissue from rheumatoid arthritis patients: a possible role for a key neurotransmitter in synovial inflammation","volume":"60","author":"van Maanen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib34","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1371\/journal.pmed.0030338","article-title":"Regulation of peripheral inflammation by spinal p38 MAP kinase in rats","volume":"3","author":"Boyle","year":"2006","journal-title":"PLoS Med"},{"key":"10.1136\/ard.2010.134684_bib35","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib36","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1056\/NEJMra040226","article-title":"Therapeutic strategies for rheumatoid arthritis","volume":"350","author":"O'Dell","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.134684_bib37","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.134684_bib38","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/0003-4819-103-4-489","article-title":"Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study","volume":"103","author":"Andersen","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2010.134684_bib39","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/art.1780290702","article-title":"The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis","volume":"29","author":"Kremer","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib40","doi-asserted-by":"crossref","first-page":"833","DOI":"10.7326\/0003-4819-121-11-199412010-00002","article-title":"Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial","volume":"121","author":"Morgan","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2010.134684_bib41","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199605163342002","article-title":"Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications","volume":"334","author":"O'Dell","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.134684_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJM199507203330301","article-title":"Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group","volume":"333","author":"Tugwell","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.134684_bib43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"key":"10.1136\/ard.2010.134684_bib44","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/S0140-6736(98)08513-4","article-title":"Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group","volume":"353","author":"M\u00f6tt\u00f6nen","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ard.2010.134684_bib45","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1136\/ard.2010.134684_bib46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.134684_bib47","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib48","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.134684_bib49","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/ard.2007.071092","article-title":"Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open label strategy trial)","volume":"66","author":"Verstappen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.134684_bib50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"10.1136\/ard.2010.134684_bib51","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib52","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","article-title":"Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial","volume":"146","author":"Goekoop-Ruiterman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2010.134684_bib53","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.134684_bib54","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib55","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/art.22718","article-title":"Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis","volume":"56","author":"van der Bijl","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib56","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1136\/ard.2010.134684_bib57","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib58","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial","volume":"372","author":"Emery","year":"2008","journal-title":"Lancet"},{"key":"10.1136\/ard.2010.134684_bib59","article-title":"TEAR abstract","volume":"60","author":"Moreland","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib60","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/art.23449","article-title":"Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies","volume":"58","author":"Saunders","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib61","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1136\/ard.2009.124958","article-title":"Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice","volume":"69","author":"van der Goes","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.134684_bib62","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.134684_bib63","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-137-9-200211050-00007","article-title":"Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial","volume":"137","author":"Kremer","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2010.134684_bib64","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/art.10228","article-title":"Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial","volume":"46","author":"O'Dell","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib65","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib66","first-page":"S213","article-title":"The ARMADA trial: a double-blind placebo controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2E7) in patients with active RA on methotrexate (MTX)","volume":"44","author":"Keystone","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib67","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/art.21018","article-title":"A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study","volume":"52","author":"Lehman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib68","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.134684_bib69","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2010.134684_bib70","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.23383","article-title":"Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib71","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib72","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1136\/ard.2010.134684_bib73","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.134684_bib74","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","article-title":"Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial","volume":"374","author":"van Vollenhoven","year":"2009","journal-title":"Lancet"},{"key":"10.1136\/ard.2010.134684_bib75","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/ard.2009.126748","article-title":"Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"Knevel","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.134684_bib76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","article-title":"Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study","volume":"56","author":"Hyrich","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib77","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11926-007-0066-2","article-title":"Switching anti-TNF-alpha agents: what is the evidence?","volume":"9","author":"Erickson","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"10.1136\/ard.2010.134684_bib78","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period","volume":"8","author":"Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard.2010.134684_bib79","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"10.1136\/ard.2010.134684_bib80","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.134684_bib81","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.134684_bib82","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib83","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","article-title":"Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis","volume":"44","author":"van Ede","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib84","first-page":"481","article-title":"Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis","volume":"33","author":"Hoekstra","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.134684_bib85","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1002\/art.24034","article-title":"Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis","volume":"58","author":"Dalrymple","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib86","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jama.298.2.187","article-title":"Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis","volume":"298","author":"Wasko","year":"2007","journal-title":"JAMA"},{"key":"10.1136\/ard.2010.134684_bib87","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.134684_bib88","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.134684_bib89","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib90","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.21869","article-title":"Solid malignancies among patients in the Wegener's granulomatosis etanercept trial","volume":"54","author":"Stone","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib91","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.22504","article-title":"Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib92","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib93","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1136\/ard.2010.134684_bib94","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib95","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semarthrit.2007.05.004","article-title":"The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review","volume":"37","author":"Grinblat","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib96","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cyto.2005.12.012","article-title":"Anti-TNF therapies in the management of acute and chronic uveitis","volume":"33","author":"Hale","year":"2006","journal-title":"Cytokine"},{"key":"10.1136\/ard.2010.134684_bib97","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1055\/s-2008-1027361","article-title":"Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital","volume":"225","author":"Petropoulos","year":"2008","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1136\/ard.2010.134684_bib98","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib99","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1086\/598331","article-title":"Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis","volume":"48","author":"McDonald","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1136\/ard.2010.134684_bib100","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"key":"10.1136\/ard.2010.134684_bib101","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.57.4.209","article-title":"HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments","volume":"57","author":"O'Dell","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.134684_bib102","first-page":"20","article-title":"Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial","volume":"35","author":"Mease","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.134684_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1874312900701010001","article-title":"Rituximab for refractory rheumatoid arthritis: a 24-week open-label prospective study","volume":"1","author":"Yin Ho","year":"2007","journal-title":"Open Rheumatol"},{"issue":"Suppl 9","key":"10.1136\/ard.2010.134684_bib104","first-page":"S785","article-title":"Safety of other biologic therapies following rituximab treatment in RA patients","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib105","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.4049\/jimmunol.1001311","article-title":"Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells","volume":"185","author":"Platt","year":"2010","journal-title":"J Immunol"},{"issue":"Suppl 3","key":"10.1136\/ard.2010.134684_bib106","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1136\/ard.2008.100834","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008","volume":"67","author":"Furst","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.134684_bib107","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.20044","article-title":"Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study","volume":"50","author":"van Gaalen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib108","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/ard.62.2.120","article-title":"Anticitrullinated protein\/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage","volume":"62","author":"Meyer","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.134684_bib109","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/art.1780391105","article-title":"Minocycline in Rheumatoid Arthritis","volume":"39","author":"Reveille","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/ard.2008.088237","article-title":"Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis?","volume":"68","author":"Hider","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.134684_bib111","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib112","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/art.22552","article-title":"A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response","volume":"57","author":"American College of Rheumatology Committee to Reevaluate Improvement Criteria","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib113","first-page":"538","article-title":"Validity of single variables and indices to measure disease activity in rheumatoid arthritis","volume":"20","author":"van der Heijde","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.134684_bib114","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2010.134684_bib116","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard.2010.134684_bib117","first-page":"603","article-title":"Time to score quantitative rheumatoid arthritis measures: 28-Joint Count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores","volume":"35","author":"Yazici","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.134684_bib118","first-page":"2410","article-title":"A composite disease activity scale for clinical practice, observational studies, and clinical trials: the Patient Activity Scale (PAS\/PAS-II)","volume":"32","author":"Wolfe","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.134684_bib119","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/art.21570","article-title":"The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden","volume":"54","author":"Kristensen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib120","first-page":"1522","article-title":"A new disease activity index for rheumatoid arthritis: Mean Overall Index for Rheumatoid Arthritis (MOI-RA)","volume":"35","author":"M\u00e4kinen","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.134684_bib121","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.134684_bib122","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib123","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1002\/art.27580","article-title":"The 2010 American College of Rheumatology\/European League Against Rheumatism classification criteria for rheumatoid arthritis: phase 2 methodological report","volume":"62","author":"Neogi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.134684_bib124","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"}],"updated-by":[{"DOI":"10.1136\/ard.2010.134684corr1","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000}}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724147802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724147802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2010.134684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:31:07Z","timestamp":1737437467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724147802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":124,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0003496724147802"],"URL":"https:\/\/doi.org\/10.1136\/ard.2010.134684","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State-of-the-art: rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2010.134684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}